Myosin light-chain kinase contributes to the proliferation and migration of breast cancer cells through cross-talk with activated ERK1/2.
about
Myosins as fundamental components during tumorigenesis: diverse and indispensableNon-muscle myosin II in disease: mechanisms and therapeutic opportunitiesMTA2 promotes gastric cancer cells invasion and is transcriptionally regulated by Sp1MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data.Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2.Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genisteinGenes influenced by the non-muscle isoform of Myosin light chain kinase impact human cancer prognosisIgE regulates the expression of smMLCK in human airway smooth muscle cells.Arsenic and chromium in drinking water promote tumorigenesis in a mouse colitis-associated colorectal cancer model and the potential mechanism is ROS-mediated Wnt/β-catenin signaling pathway.Association of a functional polymorphism (Gln261Arg) in 12-lipoxygenase with breast cancer.Matrine inhibits diethylnitrosamine-induced HCC proliferation in rats through inducing apoptosis via p53, Bax-dependent caspase-3 activation pathway and down-regulating MLCK overexpressionDownregulation of Dickkopf-1 is responsible for high proliferation of breast cancer cells via losing control of Wnt/beta-catenin signaling.Myosin light chain kinase is responsible for high proliferative ability of breast cancer cells via anti-apoptosis involving p38 pathway.A novel positive feedback loop involving FASN/p-ERK1/2/5-LOX/LTB4/FASN sustains high growth of breast cancer cells.New approaches to targeting the actin cytoskeleton for chemotherapy.Cellular plasticity: the good, the bad, and the ugly? Microenvironmental influences on progenitor cell therapy.Identification of key pathways and genes influencing prognosis in bladder urothelial carcinomaSuppression of A549 cell proliferation and metastasis by calycosin via inhibition of the PKC‑α/ERK1/2 pathway: An in vitro investigation.ML-7 amplifies the quinocetone-induced cell death through akt and MAPK-mediated apoptosis on HepG2 cell line.Mass spectrometry based quantitative proteomics and integrative network analysis accentuates modulating roles of annexin-1 in mammary tumorigenesis.Hepatitis B virus X protein accelerates hepatocarcinogenesis with partner survivin through modulating miR-520b and HBXIP.Phenylboronic acid is a more potent inhibitor than boric acid of key signaling networks involved in cancer cell migration.Proteomic analysis of human epithelial ovarian cancer xenografts in immunodeficient mice exposed to chronic psychological stress.Myosin Va plays essential roles in maintaining normal mitosis, enhancing tumor cell motility and viability.Molecular mechanisms of OLIG2 transcription factor in brain cancer.Identification of potential tissue-specific cancer biomarkers and development of cancer versus normal genomic classifiers.Inhibition of fucosylation in human invasive ductal carcinoma reduces E-selectin ligand expression, cell proliferation and ERK1/2 and p38 MAPK activation.The LPI/GPR55 axis enhances human breast cancer cell migration via HBXIP and p-MLC signaling.Overexpression of myosin is associated with the development of uterine myoma.
P2860
Q26749344-EB9E5A83-0324-46F1-BF82-70239ECE06D3Q26778962-1F0F47E1-D745-4EE4-9DE9-AFE9405989D5Q28297974-A6CD5D5D-54DE-4EA9-8A93-F894244CA896Q30847076-601792B2-D178-437A-9DBC-1A7F12218494Q33619820-F5C49C4A-D9C0-4335-A74D-81C70DBC9389Q34454890-3DB25BD9-CE4B-4E57-839C-D9664C6A66C0Q35142928-D7650A47-59DB-43A7-8447-7DEB454E5D3BQ35145449-6587700C-AB07-43CA-AAB9-0E3B2AADC7F2Q35600524-BB59C858-88B0-4058-B997-2D7A8A790C3EQ36230542-EF820387-6772-4F4F-A7DD-081C7F1211E2Q37246388-6F44DCA7-76C5-4B21-8309-DE5B2208DBD9Q37728985-857CEC97-C0CA-4E42-8244-CC602F57479FQ37729230-C02978EB-9A5E-4B92-B359-97E5D8F90AC7Q37729512-B99BCED5-0E99-4006-9601-9862B914FCF4Q37855886-FF6B73B2-146B-4D29-9829-44CDDCF102BEQ37987270-3DD3C22C-23AB-43F2-8486-FED472262185Q38435311-C259BF07-A0E4-4EA1-9C56-BEA88D41007CQ38543965-C9C260AB-215F-4232-8A0A-5FEA6D625F31Q38829588-C83637E8-AFCE-42AE-A747-EB3AE82E1523Q38965958-56C7806E-5C7E-4E45-A0A9-FEE35474F74FQ38989340-97A4B21B-BD90-4966-AF35-127066FD74E4Q39177459-AD43A869-775F-4784-B5ED-B3FFE6759943Q39592859-873F4EE1-DC27-4256-96AD-E2143590C0CAQ41551108-1F96A9EB-5419-43C2-9D02-485F8286160EQ41810203-9C0DA0E7-50C4-43D0-9BFE-BE086BFC27DAQ45943755-C6956C08-8EB9-44E2-9F43-8012A980EDF2Q47272986-0A30DF50-B5CC-4427-9097-4AE625AFC9D8Q47300195-648ADC95-644D-41D3-97D1-F98288842D61Q54192995-DA5EE7B8-D06A-403C-B040-C05E51F10DBE
P2860
Myosin light-chain kinase contributes to the proliferation and migration of breast cancer cells through cross-talk with activated ERK1/2.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Myosin light-chain kinase cont ...... ss-talk with activated ERK1/2.
@en
Myosin light-chain kinase cont ...... ss-talk with activated ERK1/2.
@nl
type
label
Myosin light-chain kinase cont ...... ss-talk with activated ERK1/2.
@en
Myosin light-chain kinase cont ...... ss-talk with activated ERK1/2.
@nl
prefLabel
Myosin light-chain kinase cont ...... ss-talk with activated ERK1/2.
@en
Myosin light-chain kinase cont ...... ss-talk with activated ERK1/2.
@nl
P2093
P1433
P1476
Myosin light-chain kinase cont ...... ss-talk with activated ERK1/2.
@en
P2093
Hang Zhang
Jiacong You
Xiaodong Zhang
Xiaolei Zhou
P304
P356
10.1016/J.CANLET.2008.05.028
P407
P577
2008-08-16T00:00:00Z